To estimate the proportion of oncocytic renal neoplasms diagnosed on renal mass biopsy (RMB) confirmed on surgical pathology, a systematic review of MEDLINE, Embase, and the Cochrane databases (1997 to 1 July 2016) was conducted quantifying all cases of reported oncocytic renal neoplasms on RMB suggestive of an oncocytoma. In addition, institutional data was assessed to identify additional cases. Concordance with surgical histopathology (positive predictive value [PPV]) was evaluated for patients undergoing surgery by performing a meta-analysis. In all, 10 RMB series, including institutional data, were included in the metaanalysis with 205 RMBs identifying oncocytic renal neoplasms and 46 (22.4%) proceeding to surgery. One additional study identified two neoplasms not captured by the primary RMB series for a total of 48 unique lesions included in the analysis. Surgical pathology showed oncocytoma (64.6%), chromophobe renal cell carcinoma (RCC; 12.5%), other RCC (12.5%), hybrid oncocytic/chromophobe tumour (6.3%), and other benign lesions (4.2%). PPV of oncocytoma on RMB was 67% (95% confidence interval 34-94%) with significant heterogeneity between studies (I 2 = 71.8%, P < 0.01). Risk of bias was judged to be low for four of the 10 series. Confidently diagnosing a localised renal mass as a benign lesion, such as an oncocytoma, has implications for the ultimate management strategy a patient will undergo. RMB was found to be unreliable in confidently diagnosing a localised renal mass as an oncocytoma, with one in four found to be RCC on surgical pathology. Patients and physicians should be aware of the uncertainty in diagnosis when considering management strategies.
Introduction
An oncocytoma is a tumour composed of epithelial cells with eosinophilic cytoplasm due to an abundance of mitochondria. Oncocytomas can form in a number of organs including the salivary glands, the thyroid gland, and the kidneys [1] . Renal oncocytomas are benign lesions, which can be difficult to distinguish from rare variants of renal cell carcinoma (RCC) [2] . The diagnosis of a localised renal mass as an oncocytoma on percutaneous renal mass biopsy (RMB) has particularly important implications for downstream management decisions. With increasing incidental diagnosis of asymptomatic, clinically localised renal masses, series show 20% of resected tumours are ultimately found to be benign [3, 4] . Nephrectomy for a renal mass suspected to be an oncocytoma risks unnecessarily losing part or whole of a renal unit to treat a benign tumour, while active surveillance may delay intervention for a RCC in the event of a misdiagnosis.
Prior studies have questioned the accuracy of RMB to diagnose oncocytomas, but there is a sparsity of data [5] . Additionally, to our knowledge, no study has systematically reviewed the correlation between RMB and surgical pathology for suggested oncocytomas. Thus, we performed a systematic review and meta-analysis of the available literature and institutional data to obtain an estimate of the proportion of oncocytic renal neoplasms on RMB that are confirmed to be oncocytomas on surgical pathology (positive predictive value [PPV] ). We quantified discordant cases and aimed to tabulate indications for intervention when possible.
Materials and Methods
We performed a systematic review and meta-analysis of RMB series in the literature (MEDLINE, Embase, Cochrane databases) for clinically localised renal masses that included any patients diagnosed with an oncocytic renal neoplasm on RMB suggestive of an oncocytoma who underwent extirpation. Studies were identified based on a recent Agency for Healthcare Research and Quality (AHRQ) systematic review on diagnostic accuracy of RMB to identify malignancy for localised renal tumours [6, 7] . The study period for the systematic review (1 January 1997 to 1 May 2015) was updated to 1 July 2016 to identify any additional relevant studies. The methods have been previously described in detail [6] [7] [8] .
We limited our inclusion criteria to studies with core biopsy data allowing surgical histopathological correlation to RMB. Data from included studies, when not directly reported or available in the published manuscripts, were obtained through direct communication with the study authors and institutions where the studies were conducted. Data from a retrospective cohort of patients undergoing RMB at Johns Hopkins Hospital (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , previously published only as an abstract, was included by restricting analysis to patients diagnosed with an oncocytic renal neoplasm suggestive of an oncocytoma without additional suspicion for carcinoma on core biopsy [Engineering and Urology Society, 31st Annual Meeting, 7 May 2016]. Patients with additional ipsilateral masses suspicious for RCC on RMB were excluded. Indications for immediate or delayed intervention were tabulated when possible. Two reviewers independently assessed risk of bias for individual studies using the modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Publication bias was explored with a funnel plot.
To our knowledge, no studies have previously reported performance characteristics or pooled histopathological correlation parameters for RMB to diagnose oncocytomas. We used an established statistical program (metaprop) within Stata version 12.0 [9] to allow random effects modelling and Freeman-Tukey double arcsine transformation to stabilise variances for binomial data. The method prevents bias in the pooled estimate that can result from proportions close to 1.0 or 0.0 that would conventionally be excluded from analysis. In this case, the proportion of oncocytic renal neoplasms confirmed to be oncocytomas on surgical pathology corresponds to the PPV of oncocytoma on RMB [10] . Sensitivity and specificity could not be accurately assessed because most of the tumours did not undergo extirpation. Heterogeneity was assessed by computing the I 2 statistic.
Results

Summary of Studies
From 20 829 unique citations screened related to RMB for localised renal tumours in the AHRQ systematic review, eight met criteria to be included in the present systematic review of surgical histopathological correlation for oncocytomas diagnosed on RMB ( Fig. 1 ) [11] [12] [13] [14] [15] [16] [17] [18] . Two studies were from the same institution but with different inclusion criteria and range of years, so both were evaluated [12, 18] . Some tumours overlapped, but only unique oncocytic renal neoplasms on biopsy were included in the meta-analysis. In the update through to 1 July 2016, 486 additional articles were screened with one additional study meeting inclusion criteria [19] . An update of one series from Australia focused on oncocytic renal neoplasms on RMB undergoing surgery included two additional lesions, which were also included [13, 20] . All studies evaluated core biopsy and included at least one patient with oncocytic renal neoplasm on biopsy that underwent surgery. Most studies described obtaining two or more biopsy cores with a 17-G coaxial introducer and 18-G biopsy needle. Studies often did not fully describe their biopsy processing techniques but most described using haematoxylin and eosin staining and specific stains for non-renal cell (Hale's colloidal iron) or RCC subtypes (immunohistochemistry). The reviewed studies included 1 633 patients (Table 1) [ [11] [12] [13] [14] [15] [16] [17] [18] [19] with a total of 1 657 tumours ( (Table S2) . Across all studies, 205 RMBs (12.2% off all diagnostic biopsies) showed oncocytic cells, and 46 (22.4%) unique masses proceeded to surgery. Two additional lesions were identified in an update of one series for a total of 48 included masses for metaanalysis [20] .
Systematic Review and Meta-Analysis of Oncocytic Renal Neoplasms
The systematic review showed that 31 of 48 (64.6%) oncocytic neoplasms on RMB were found to be oncocytomas on surgical pathology (Table 3 ; Fig. 2 ) [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
A notable proportion were found to be chromophobe RCC (six of 48; 12.5%) but equally as many were found to be other variants of RCC (six of 48; 12.5%). The remainder were indolent (hybrid oncocytic/chromophobe tumour [HOCT] in three of 48; 6.3%) or papillary adenomas (two of 48; 4.2%). Meta-analysis determined the PPV of oncocytoma on RMB to be 67% (95% CI 34-94%) with significant heterogeneity between studies (I 2 = 71.8%, P < 0.01) (Fig. 3) . Risk of bias assessments showed four of the 10 studies to be at low risk of bias with the remainder judged to be at high risk of bias due to a proportion missing reference standard evaluations (surgical pathology) for masses showing oncocytic renal neoplasms on RMB. Among only studies at low risk of bias, a similar proportion of masses were confirmed as oncocytoma on surgical pathology (19 of 28; 67.9%) or found to be RCC (seven of 28; 25%) [11, 12, 16, 17] . The process for pathological evaluation of biopsy samples in these studies did not appear to differ from other studies. Funnel plot assessment did not reveal obvious publication bias but was limited by small sample sizes across studies. 
Systematic Review of Indications for Surgery
There were multiple indications for intervention after biopsy result. Indications were reported for 22 of 48 (45.8%) masses. One study, judged to be at low risk of bias, noted that all patients in the study underwent extirpation regardless of biopsy result with three of four masses showing RCC and one mass confirmed to be an oncocytoma [17] . Of the remaining 18 masses, eight (44.4%; five oncocytoma, two chromophobe RCC, and one HOCT) underwent surgery for patient preference and five (27.8%; four oncocytoma and one clear cell RCC) for growth while on active surveillance. Other indications included multifocality for one case (confirmed oncocytoma), size of lesion for one tumour (7.6 cm; found to be chromophobe RCC), and placement on transplant recipient list for three tumours (one unclassified RCC in one patient; two bilateral papillary adenomas in one patient).
Discussion
A systematic review of the literature revealed nine articles, which along with institutional data, totalled 205 RMBs (12.2% of diagnostic biopsies) of localised renal tumours showing oncocytic renal neoplasms suggestive of oncocytomas. Only a fraction of these (22.4%) underwent surgery with a significant proportion (35.4%) showing histopathological results other than oncocytoma. The PPV of oncocytic neoplasm on biopsy to diagnose oncocytomas on surgical pathology was found to be 67% (95% CI 34-94%) on pooled meta-analysis. Results were similar when restricting to studies at low risk of bias. Indication for intervention did not appear associated with histopathology. The findings question the confidence in the other masses diagnosed as oncocytomas on RMB across studies that did not proceed to surgery for confirmation.
The finding that one out of three RMBs suggesting a diagnosis of an oncocytoma will ultimately be incorrect, and that one out of four will actually have RCC, has implications for the role of RMB in the diagnosis of localised renal tumours. While the PPV of diagnosing malignancy on RMB is known to be very high (>99%), a benign result leads to a conundrum in terms of management due to a poor NPV (~70%) [6, 21] . It is interesting to note that this NPV is similar in magnitude to the PPV for diagnosing oncocytoma, as many benign biopsy results show oncocytoma. Admittedly, retrospective RMB cohorts often include historical diagnoses of renal oncocytic neoplasms that may not have had a dedicated genitourinary pathologist confirming all pathology reviews. There are also differing levels of confidence in diagnosing an oncocytic neoplasm on RMB that relies on the biopsy sample being representative of the overall renal tumour. However, the systematic review summarises the available literature given the small proportion of patients who will undergo surgery after diagnosis of an oncocytic renal neoplasm and reinforces the need for improving methods to perform RMB, dedicated pathology review of RMBs, and evaluation of non-invasive methods to supplement diagnosis. A recent cohort notes that placing oncocytic renal neoplasms diagnosed on RMB on active surveillance appears safe, but some degree of uncertainty remains [22] . Promisingly, a recent trial evaluating the utility of non-invasive imaging with 99m Tc-sestamibi single-photon emission CT/X-ray CT showed high sensitivity (87.5%) and specificity (95.2%) for identifying oncocytoma or HOCT, and no papillary or clear cell RCC was misclassified [23] .
Differentiation of malignant eosinophilic renal tumours from benign oncocytomas can be difficult and often relies on immunohistochemistry in addition to histological morphology for the most reliable diagnosis [1, 24] . Therefore, diagnosis on biopsy samples can be challenging even if an adequate specimen is obtained using current standards of good practice (18-G biopsy needle, ≥2 cores, staining techniques for RCC subtypes and non-RCC histologies). The result of oncocytoma on RMB can lend support to a shared patient-physician decision to pursue active surveillance with preserved quality of life, but careful follow-up is needed given the rate of misclassification and similar growth rate of oncocytomas to RCC when on active surveillance [25, 26] . Other predictors of malignancy, beyond tumour size and sex, have not been shown to aid in this process [27] . A recent in-depth analysis of morphology and immunohistochemistry of renal oncocytic neoplasms on RMB by two expert genitourinary pathologists suggested the ability to categorise 67% of lesions as 'favour oncocytoma', a similar proportion as were confirmed on surgical pathology in the meta-analysis [28] . They further categorised 12% to 'favour RCC' and 21% as 'cannot exclude RCC' with fair confirmation for the subset with surgical pathology available. Advances in non-invasive imaging and immunohistochemistry will aid risk-stratification to reduce the proportion of benign lesions removed due to uncertainty.
The limitations of the present study deserve mention. The individual cohorts included are limited by small sample size, their retrospective nature, and inability to perform histopathological correlation for patients with oncocytic renal neoplasm on RMB who did not undergo extirpation. A final common limitation of institutional RMB studies, mentioned previously, is lack of consistent centralised genitourinary pathologist review and differing levels of certainty of neoplasms assigned the classification of oncocytic renal neoplasm.
Conclusion
In summary, RMB was found to be unreliable in confidently diagnosing a localised renal mass as an oncocytoma with one in four found to be RCC on surgical pathology. Available evidence suggests many oncocytic renal neoplasms diagnosed on RMB can be safely monitored on active surveillance, and future prospective studies on immunohistochemistry and promising emerging imaging modalities will help to augment confidence [23] . Patients and physicians should be aware of the uncertainty in diagnosis when considering management strategies. Oncocytoma on renal mass biopsy
